Printer Friendly

Articles from M2 Pharma (November 8, 2017)

1-32 out of 32 article(s)
Title Author Type Words
Aldevron unveils GMP SpCas9 gene editing enzymes for clinical trials. 197
Alligator Bioscience reports result from clinical phase I study support further clinical development of ADC-1013. 239
Apeiron Biologics names new chief financial officer and chief business officer. 160
Australian Health Department Approves Inclusion of Aytu BioScience MiOXSYS System for Male Infertility Evaluation on Therapeutic Goods Register. 223
Boehringer Ingelheim releases one-year data from trial assessing Cyltezo. 199
Cerenis Therapeutics acquires LYPRO Biosciences. 221
ClearLight Diagnostics awarded exclusive intellectual property rights for its novel CLARITY-based tissue clearing instrumentation. 184
Cosentyx Reduces Structural Joint Damage in Psoriatic Arthritis Compared to Placebo. 289
FDA Approves Zelboraf for Erdheim-Chester Disease with BRAF V600 Mutation. 526
Hookipa names new chairman of board of directors. 150
Ionis Submits NDA for Inotersen to the US FDA. 248
Janssen announces primary endpoint from Phase 2 study of STELARA (ustekinumab) in lupus patients. Clinical report 314
Kolon Life Science launches osteoarthritis drug in Korea. 164
Longer-Term Results of Phase 2 Study Demonstrate Continued Efficacy of Tremfya in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis. 229
Lycera Selects Multiple Solid Tumors Types for Phase 2a Study of RORgamma Agonist. 294
Nektar Therapeutics swings to net income of USD60.9m for Q3 2017. 216
Neurelis Inc announces patent allowance in Japan for NRL-1 intranasal diazepam formulation for epilepsy patients. 258
NeuroVive announces resignation of chair of board. 173
Nitto Avecia successfully completes multiple oligonucleotide manufacturing synthesis runs at 1.6 Mol scale in Milford, MA. 152
Novartis seeks approval for CTL019 from European Medicines Agency. 202
Novartis to present positive topline results from global MONALEESA-7 trial. 233
Novus Therapeutics Promotes Dr. Catherine Turkel to President. 289
OncoSec names Daniel J. O'Connor as CEO. 186
OrthoTrophix Study of TPX-100 Shows Improvement in Knee Activity and Pain Reduction Compared to Placebo. Clinical report 288
Phase 2b International Study Results Show 95% Efficacy of Mino Lok in Salvaging Infected Catheters. 210
Promising results from malaria breath test clinical trial. 608
Remedium Wellness announces availability of new ED treatment GAINSWave. 168
Roche wins US FDA for VENTANA ALK (D5F3) CDx Assay to identify ALK-positive non-small cell lung cancer (NSCLC) patients. 263
SiteOne Therapeutics Receives USD 1m Research Grant from US DoD to Advance Acute and Chronic Pain Therapeutics. 339
The US Food and Drug Administration withdraws clinical hold on Cellectis' Phase one trials of UCART123. 246
ThromboGenics strengthens senior leadership team with two new appointments. 235
XVIVO Perfusion announces new reimbursement codes for US hospitals for doctors' time during EVLP procedures. 259

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters